Compare Ascendis Pharma A/S (ASND) vs MasterCard Inc (MA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs MasterCard Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while MasterCard Inc trades at $528.01 (market cap $465.42B). The key difference: MasterCard Inc is far larger — about 26.2× Ascendis Pharma A/S's market cap, and MasterCard Inc pays a 0.66% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | MA | |
|---|---|---|
Market Cap | $17.74B | $465.42B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $598.96 |
52-Week Low | $163.32 | $471.55 |
Enterprise Value | $18.11B | $476.16B |
Volume | — | 4,635,698 |
Dividend Yield | — | 0.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Mastercard (MA) trades at $526.74, up 0.68% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats, 45.88% net margins, and robust revenue growth from $22.2B in 2022 to $32.8B in 2025. Analyst consensus is strongly bullish with a $637.67 price target and 79% buy ratings. Recent institutional buying and dividend payments of $0.87 per share support positive sentiment.
Mastercard presents a compelling growth opportunity with expanding global payments infrastructure and AI integration. Risks include payment disruption from stablecoins and competitive pressures. The stock trades at a premium valuation (P/E 30.48) but justifies it through superior profitability and market leadership position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
